Please assess the completion status of the following clinical trial:

Trial Title: Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and Women ≥ 18 years of age~* Diagnosed with stage IV Non-Small Cell Lung Cancer~* Diagnosed with recurrent stage IIIB non-small cell lung cancer and failed previous concurrent chemoradiation with no further curative options.~Exclusion Criteria:~* Subjects with untreated CNS metastases are excluded.~* Subjects with carcinomatous meningitis~* Subjects with an active, known or suspected autoimmune disease.~* Subjects with a condition requiring systemic treatment with either corticosteroids ( \> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first treatment.~* Women who are pregnant, plan to become pregnant, and/or breastfeed during the study.~Other protocol defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab+Ipilimumab (Type: EXPERIMENTAL): Part 1~Specified Dose on Specified Days
- Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy (Type: EXPERIMENTAL): Part 2~Specified Dose on Specified Days

Based on this trial design, predict the completion outcome and termination type (if applicable).